{
    "nct_id": "NCT05633667",
    "official_title": "A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung)",
    "inclusion_criteria": "All Substudies:\n\n* Histologically or cytologically documented non-small-cell lung cancer (NSCLC).\n* No known actionable genomic alterations for which targeted therapies are available.\n* Eastern cooperative oncology group (ECOG) performance status score of 0 or 1.\n* Measurable disease per response evaluation criteria in solid tumors.\n* Adequate hematologic and end-organ function.\n* Individuals of childbearing potential who engage in heterosexual intercourse must agree to use specified method(s) of contraception.\n\nSubstudy 01: All Experimental arms\n\n* Stage IV NSCLC.\n* For individuals with nonsquamous histology: Epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) alteration negative.\n* PD-L1 status by central confirmation.\n* No prior systemic treatment for metastatic NSCLC.\n\nSubstudy 02: All Experimental arms\n\n* Stage IV NSCLC.\n* In individuals with nonsquamous histology and actionable EGFR, ALK, or other known genomic alterations must have received treatment with at least 1 targeted therapy to the appropriate genomic alteration.\n\nSubstudy 03: All Experimental arms\n\n* Previously untreated individuals with resectable (Stage II, IIIA, IIIB (T[3-4]N2) NSCLC (per American Joint Committee on Cancer (AJCC) Edition 8).\n* Planned surgery must comprise of lobectomy, sleeve lobectomy, or bi-lobectomy.\n* PD-L1 status by central confirmation.\n* For individuals with nonsquamous histology: Epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) alteration negative.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "All Substudies:\n\n* Mixed small-cell lung cancer and NSCLC histology.\n* Active second malignancy.\n* Active autoimmune disease.\n* History of or current non-infectious pneumonitis/interstitial lung disease.\n* Active serious infection within 4 weeks prior to study treatment.\n\nSubstudy 01 and 02\n\n* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.\n* Received previous anticancer therapy within 4 weeks prior to enrollment.\n\nSubstudy 03: All Experimental arms\n\n* NSCLC previously treated with systemic therapy or radiotherapy.\n* Received prior treatment with any anti-PD-(L)-1 or other immune checkpoint inhibitors (CPIs).\n\nNote: Other protocol defined inclusion/exclusion criteria may apply",
    "miscellaneous_criteria": "Key"
}